$599

Arrowhead Q3 ’26 Earnings; Lilly Breaks Ground on US Manufacturing Facility; Tandem Mobi Tubeless FDA Clearance; November CHMP Highlights; AbbVie Skyrizi + Amylin Combo PsO Study; Vivani Topline Ph1 Sema Implant Data

A series of cardiometabolic-related news items has been observed from Arrowhead Pharmaceuticals, Lilly, Tandem Diabetes Care, EMA, AbbVie, and Vivani Medical. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here